Literature DB >> 30482560

Evaluation of FDG PET combined with cardiac MRI for the diagnosis and therapeutic monitoring of cardiac sarcoidosis.

B Sgard1, P-Y Brillet2, D Bouvry3, S Djelbani1, H Nunes3, C Meune4, D Valeyre3, M Soussan5.   

Abstract

AIM: To compare combined 2-[18F]-fluoro-2-deoxy-d-glucose (FDG)-positron-emission tomography (PET) and cardiac magnetic resonance imaging (CMR) for the diagnosis and therapy monitoring of cardiac sarcoidosis (CS).
MATERIALS AND METHODS: Eighty patients with sarcoidosis and a suspicion of CS who underwent PET and CMR were included retrospectively. PET was undertaken after a low-carbohydrate-high-fat diet in all patients using a combined 16-section PET/computed tomography (CT) camera. PET was considered positive (PET+) in cases of focal or multifocal FDG uptake. CMR was considered positive (CMR+) in cases of subepicardial late gadolinium enhancement (LGE). A subgroup of 50 patients (50/80) was monitored during therapy and classified as responders or non-responders.
RESULTS: Eighty-two percent of patients with PET+ (9/11) also had CMR+ imaging, with good spatial agreement (kappa=0,79; 95% confidence interval [CI]: 0.65-0.94). Twenty-seven percent (22/80) had residual physiological FDG uptake, with a standardised uptake value (SUV) not significantly different compared to the SUV from pathological uptake (6.4 versus 6 respectively, p=0,92). The clinical response was more frequent in patients with baseline PET+ compared to baseline PET- (80% versus 45%, p=0.07). PET findings improved in all cases under treatment (7/7), whereas LGE improved in only 33% of patients (3/9).
CONCLUSION: Due to high risk of false-positive or undetermined findings, PET might be performed as a second-line study in cases of LGE, to assess inflammatory load. In addition, PET seems suitable to predict and assess response under therapy.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30482560     DOI: 10.1016/j.crad.2018.09.015

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  6 in total

Review 1.  The role of positron emission tomography in the assessment of cardiac sarcoidosis.

Authors:  Dario Genovesi; Matteo Bauckneht; Corinna Altini; Cristina Elena Popescu; Paola Ferro; Lavinia Monaco; Anna Borra; Cristina Ferrari; Federico Caobelli
Journal:  Br J Radiol       Date:  2019-06-05       Impact factor: 3.039

2.  Utility of FDG PET and Cardiac MRI in Diagnosis and Monitoring of Immunosuppressive Treatment in Cardiac Sarcoidosis.

Authors:  Richard A Coulden; Emer P Sonnex; Jonathan T Abele; Andrew M Crean
Journal:  Radiol Cardiothorac Imaging       Date:  2020-08-27

3.  COMPARISON OF THE EFFECT OF THREE DIFFERENT DIETARY MODIFICATIONS ON MYOCARDIAL SUPPRESSION IN 18F-FDG PET/CT EVALUATION OF PATIENTS FOR SUSPECTED CARDIAC SARCOIDOSIS.

Authors:  Can Ozutemiz; Yasemin Koksel; Jerry W Froelich; Nathan Rubin; Maneesh Bhargava; Henri Roukuz; Rebecca Cogswell; Jeremy Markowitz; David M Perlman; Daniel Steinberger
Journal:  J Nucl Med       Date:  2021-03-26       Impact factor: 11.082

4.  Cardiac magnetic resonance imaging-negative cardiac sarcoidosis.

Authors:  See-Yue Arthur Yung; James Chung-Man Ho; Maximus C F Yeung; Carmen Chan; Chung-Wah Siu
Journal:  HeartRhythm Case Rep       Date:  2021-01-01

5.  The usefulness of repeated CMR and FDG PET/CT in the diagnosis of patients with initial possible cardiac sarcoidosis.

Authors:  H Mathijssen; T W H Tjoeng; R G M Keijsers; A L M Bakker; F Akdim; H W van Es; F T van Beek; M V Veltkamp; J C Grutters; M C Post
Journal:  EJNMMI Res       Date:  2021-12-20       Impact factor: 3.138

Review 6.  The role of PET in the management of sarcoidosis.

Authors:  Robert J Vender; Hamad Aldahham; Rohit Gupta
Journal:  Curr Opin Pulm Med       Date:  2022-07-16       Impact factor: 2.868

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.